All In Biotech

Free tool

FAERS Monitor: Kygevvi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 219792 or its brand name (Kygevvi, Doxecitine, Doxribtimine). Reports on generic versions are filed under their own applications.

Reports

34

Serious

13

38% of reports

Hospitalization

6

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea11
  • off label use11
  • vomiting6
  • femur fracture5
  • gastrostomy5
  • pneumonia5
  • tracheostomy5
  • bradycardia3
  • illness3
  • tracheitis3
  • anxiety2
  • asthenia2
  • depression2
  • endotracheal intubation2
  • headache2

Reports by year received

View as table
YearReports
202634

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,125 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
tracheitisSignal32447.6828.85,074
tracheostomySignal52172.8965.48,761
gastrostomySignal52002.7890.08,076
endotracheal intubation2441.7115.1494
femur fractureSignal599.944.5396
bradycardiaSignal335.011.968
illnessSignal318.06.133
diarrhoeaSignal1110.56.588
pneumoniaSignal59.64.331
vomitingSignal67.93.830
off label useSignal117.84.861
depression25.41.44
anxiety24.31.12
asthenia23.30.91
headache22.00.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.